Literature DB >> 22346284

Maximal Points of Head's Zone in Fixed Drug Eruption.

Sang Sin Lee1, Dong Kyun Hong, Myung Im, Young Lee, Young Joon Seo, Jeung Hoon Lee.   

Abstract

The principles determining the primary localization of lesions in fixed drug eruption (FDE) are still unknown. Studies investigating the predilection areas in FDE have indicated drug-related, trauma-related, or inflammation-related specific site involvement, as well as visceracutaneous reflex-related specific site involvement. The importance of viscerocutaneous reflexes for the location of dermatoses was first recognized in the 1960s. Head's zones are viscerocutaneous reflex projection fields on the skin that extend over certain dermatomes and possess a reflex-associated maximal point. Recently, in a Turkish collective of patients, three women with the primary location of FDE lesions on the maximal points of Head's zones were presented. We also experienced 3 cases with FDE where the lesions were located at specific sites (buttocks), the so-called maximal points of Head's zones, which are known to be the most active dermatomal areas of an underlying visceral pathology. An underlying internal disturbance (ureter stone, pyelonephritis and chronic pelvic inflammatory disease) was found in all 3 patients, corresponding to the organ-related maximal point of Head's zones in each case. In conclusion, the primary location of FDE lesions on the maximal points of Head's zones revealed relevant organ disorders with corresponding projection fields.

Entities:  

Keywords:  Fixed drug eruption; Maximal points of Head's zone; Viscerocutaneous refle

Year:  2011        PMID: 22346284      PMCID: PMC3276803          DOI: 10.5021/ad.2011.23.S3.S383

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


  13 in total

1.  Reflex therapy in dermatology.

Authors:  G Stüttgen
Journal:  Clin Dermatol       Date:  1999 Jan-Feb       Impact factor: 3.541

Review 2.  Pathophysiology of fixed drug eruption: the role of skin-resident T cells.

Authors:  Tetsuo Shiohara; Yoshiko Mizukawa; Yuichi Teraki
Journal:  Curr Opin Allergy Clin Immunol       Date:  2002-08

3.  Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption.

Authors:  Yoshiko Mizukawa; Yoshimi Yamazaki; Yuichi Teraki; Jun Hayakawa; Kazuhito Hayakawa; Hideko Nuriya; Michinori Kohara; Tetsuo Shiohara
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

Review 4.  The immunological basis of lichenoid tissue reaction.

Authors:  Tetsuo Shiohara; Yoshiko Mizukawa
Journal:  Autoimmun Rev       Date:  2004-12-13       Impact factor: 9.754

Review 5.  Fixed drug eruption (FDE): changing scenario of incriminating drugs.

Authors:  Virendra N Sehgal; Govind Srivastava
Journal:  Int J Dermatol       Date:  2006-08       Impact factor: 2.736

Review 6.  Fixed drug eruption. A brief review.

Authors:  W Korkij; K Soltani
Journal:  Arch Dermatol       Date:  1984-04

7.  Fixed drug eruption: primary site involvement on maximal points of Head's zones.

Authors:  Esen Ozkaya
Journal:  Acta Derm Venereol       Date:  2007       Impact factor: 4.437

8.  Drug-specific clinical pattern in fixed drug eruptions.

Authors:  T P Thankappan; J Zachariah
Journal:  Int J Dermatol       Date:  1991-12       Impact factor: 2.736

9.  Specific site involvement in fixed drug eruption.

Authors:  Esen Ozkaya-Bayazit
Journal:  J Am Acad Dermatol       Date:  2003-12       Impact factor: 11.527

10.  IFN-gamma-producing effector CD8+ T cells and IL-10-producing regulatory CD4+ T cells in fixed drug eruption.

Authors:  Yuichi Teraki; Tetsuo Shiohara
Journal:  J Allergy Clin Immunol       Date:  2003-09       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.